| |
| |
|
| Insider
Information: |
Ballal Rahul D. |
| Relationship: |
Director |
| City: |
Boston |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
24,643 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$75,506 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
24,643 |
|
|
| Total
Value |
$75,506 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Enliven Therapeutics Ord Shs |
ELVN |
|
2024-04-11 |
22,341 |
2020-12-14 |
0 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2023-08-11 |
2,302 |
2023-08-11 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
18 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-11 |
4 |
AS |
$23.14 |
$1,279,068 |
D/D |
(53,400) |
22,341 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-11 |
4 |
OE |
$12.60 |
$705,266 |
D/D |
53,400 |
75,741 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-10 |
4 |
AS |
$21.01 |
$285,744 |
D/D |
(13,600) |
22,341 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-10 |
4 |
OE |
$12.60 |
$171,360 |
D/D |
13,600 |
35,941 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-04 |
4 |
AS |
$19.15 |
$66,729 |
D/D |
(3,485) |
22,341 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-04 |
4 |
OE |
$12.60 |
$43,911 |
D/D |
3,485 |
25,826 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-01 |
4 |
AS |
$19.08 |
$61,758 |
D/D |
(3,237) |
22,341 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-01 |
4 |
OE |
$5.52 |
$18,534 |
D/D |
3,237 |
25,578 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-03-20 |
4 |
AS |
$19.16 |
$254,462 |
D/D |
(13,278) |
22,341 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-03-20 |
4 |
OE |
$5.52 |
$73,295 |
D/D |
13,278 |
35,619 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-08-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,302 |
2,302 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Executive Officer |
• – – |
2023-02-22 |
4 |
S |
$4.66 |
$153,132 |
D/D |
(32,861) |
87,835 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Executive Officer |
• – – |
2023-01-30 |
4 |
S |
$3.91 |
$44,234 |
D/D |
(11,313) |
120,696 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Executive Officer |
• – – |
2022-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
131,400 |
137,009 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Executive Officer |
• – – |
2020-12-17 |
4 |
AS |
$25.00 |
$124,975 |
D/D |
(4,999) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Executive Officer |
• – – |
2020-12-17 |
4 |
OE |
$3.15 |
$15,747 |
D/D |
4,999 |
4,999 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Executive Officer |
• – – |
2020-12-14 |
4 |
AS |
$25.00 |
$25 |
D/D |
(1) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Chief Executive Officer |
• – – |
2020-12-14 |
4 |
OE |
$3.15 |
$3 |
D/D |
1 |
1 |
0 |
- |
|
18 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
